Agios Pharmaceuticals Target of Unusually High Options Trading (AGIO)

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) was the target of unusually large options trading activity on Thursday. Stock investors acquired 869 put options on the stock. This represents an increase of approximately Infinity compared to the typical daily volume of 0 put options.

A number of research analysts recently weighed in on AGIO shares. Credit Suisse Group lifted their target price on shares of Agios Pharmaceuticals from $61.00 to $66.00 and gave the company an “outperform” rating in a research note on Thursday, November 2nd. ValuEngine upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. BidaskClub cut shares of Agios Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, August 9th. Needham & Company LLC lifted their target price on shares of Agios Pharmaceuticals from $54.00 to $72.00 and gave the company a “buy” rating in a research note on Thursday, August 10th. Finally, SunTrust Banks, Inc. restated a “buy” rating and set a $80.00 target price on shares of Agios Pharmaceuticals in a research note on Wednesday, October 4th. Three analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $75.70.

Shares of Agios Pharmaceuticals (NASDAQ AGIO) opened at $62.05 on Tuesday. Agios Pharmaceuticals has a one year low of $39.24 and a one year high of $72.73.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) EPS for the quarter, topping the consensus estimate of ($1.78) by $0.19. The business had revenue of $11.35 million for the quarter, compared to analysts’ expectations of $10.85 million. Agios Pharmaceuticals had a negative net margin of 506.39% and a negative return on equity of 69.64%. The business’s quarterly revenue was up 26.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($1.63) EPS. equities research analysts anticipate that Agios Pharmaceuticals will post -6.59 earnings per share for the current fiscal year.

In related news, Director Lewis Clayton Jr. Cantley sold 4,000 shares of Agios Pharmaceuticals stock in a transaction on Wednesday, August 23rd. The shares were sold at an average price of $56.85, for a total transaction of $227,400.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Scott Biller sold 2,146 shares of Agios Pharmaceuticals stock in a transaction on Friday, September 1st. The shares were sold at an average price of $61.99, for a total transaction of $133,030.54. Following the transaction, the insider now owns 8,410 shares in the company, valued at approximately $521,335.90. The disclosure for this sale can be found here. Insiders have sold a total of 178,908 shares of company stock worth $12,147,719 in the last quarter. Corporate insiders own 10.55% of the company’s stock.

Hedge funds have recently made changes to their positions in the business. Brown Advisory Inc. increased its holdings in shares of Agios Pharmaceuticals by 8.5% in the 3rd quarter. Brown Advisory Inc. now owns 291,139 shares of the biopharmaceutical company’s stock worth $19,433,000 after buying an additional 22,736 shares during the last quarter. Schwab Charles Investment Management Inc. increased its holdings in shares of Agios Pharmaceuticals by 19.7% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 115,995 shares of the biopharmaceutical company’s stock worth $7,743,000 after buying an additional 19,129 shares during the last quarter. Amalgamated Bank increased its holdings in shares of Agios Pharmaceuticals by 12.9% in the 3rd quarter. Amalgamated Bank now owns 7,827 shares of the biopharmaceutical company’s stock worth $522,000 after buying an additional 897 shares during the last quarter. Legal & General Group Plc increased its holdings in shares of Agios Pharmaceuticals by 29.8% in the 3rd quarter. Legal & General Group Plc now owns 16,241 shares of the biopharmaceutical company’s stock worth $1,084,000 after buying an additional 3,724 shares during the last quarter. Finally, Fernwood Investment Management LLC bought a new stake in shares of Agios Pharmaceuticals in the 3rd quarter worth about $1,859,000. Institutional investors and hedge funds own 93.16% of the company’s stock.

WARNING: “Agios Pharmaceuticals Target of Unusually High Options Trading (AGIO)” was originally reported by Markets Daily and is the property of of Markets Daily. If you are reading this news story on another domain, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this news story can be viewed at https://www.themarketsdaily.com/2017/11/14/agios-pharmaceuticals-target-of-unusually-high-options-trading-agio.html.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply